

GLENMARK PHARMACEUTICALS

PHARMACEUTICALS

18 MAY 2017

Quarterly Update

BUY

Target Price: Rs 900

Q4 miss led by Zetia; execution of guidance critical

Glenmark's (GNP) Q4 PAT was below estimates due to significant miss in US sales (USD 150 mn vs. estimated USD 193 mn). The sales miss was led by lower gZetia sales (~USD 50 mn vs. est. ~USD 80 mn) and ~15% price erosion in US base business. Management expects gZetia sales to improve in Q1FY18 as 2.5 months exclusivity still remains, and expects 12-15% revenue growth in FY18. We note some improvement in B/S as 1) net debt marginally declined despite Rs 3.2bn write-off related to Venezuela & 2) net worth accretion of Rs 6.7bn in FY17

On weak Q4, miss in guidance and increasing sector headwinds, we cut FY18/19E EPS by ~10% each and TP to Rs900 (17x FY19E EPS; vs. Rs 1,120 earlier at 19x). We maintain BUY rating given GNP's strong R&D pipeline in US, steady India and improving EM# business. NCE[^] licensing income critical to improve B/S & C/F, in our view.

CMP : Rs 760
Potential Upside : 18%

MARKET DATA

No. of Shares : 282mn
Free Float : 53%
Market Cap : Rs255bn
52-week High / Low : Rs993 / Rs729
Avg. Daily vol. (6mth) : 5,57,190 shares
Bloomberg Code : GNP IB Equity
Promoters Holding : 47%
FII / DII : 35% / 6%

- ♦ **Miss in sales led by gZetia; pricing pressure:** Overall sales grew 7% YoY, but declined 3% QoQ to Rs 24.5 bn, 16% below consensus, primarily led by US (-19%QoQ). US sales (~41% of revenue) at USD 150 mn declined 18%QoQ in USD terms led by slower-than-expected ramp-up in gZetia and ~15% price erosion in base business. As per management, miss in gZetia is due to timing difference in booking sales – expected market share didn't improve as expected, and GNP had pushed significant inventory and booked sales in Q3. However, it expects gZetia sales to improve in Q1FY18 with sales to be marginally lower than USD 200mn (vs. earlier guidance of USD 200mn-250mn). We note it would have booked USD 120mn in H2FY17 and likely to book another USD 36mn in Q1FY18.
- ♦ **Margin further hit by one offs:** Gross/EBITDA margin down ~800 bps/~1,200 bps QoQ on lower gZetia sales & lower number of approvals (2 in H2'17 vs. 9 in H1'17). Op. margin was also hit by forex loss of Rs~740 mn (total Rs1.39bn); adjusting for forex loss, margin stood at 21% vs. reported 18% – still ~900 bps lower QoQ mainly on higher R&D (~14.8% of Q4 sales vs. 10.9% in Q3). Interest expense was higher due to FY end adjustment of FCCB options. Lower tax (deferred tax on lower gZetia sales, MAT credit) led to adj. PAT of Rs 4 bn, 33% below estimate

Financial summary (Consolidated)

Y/E March	FY16	FY17	FY18E	FY19E
Sales (Rs mn)	76,496	91,857	96,485	1,09,809
Adj PAT (Rs mn)	7,021	11,757	12,330	14,974
Con. EPS* (Rs)	-	-	52.7	53.2
EPS (Rs)	24.8	41.6	43.6	53.0
Change YOY (%)	(16.2)	67.4	4.9	21.4
P/E (x)	36.4	21.7	20.7	17.1
RoE (%)	19.3	25.5	22.4	22.1
RoCE (%)	15.2	19.3	18.1	19.8
EV/E (x)	20.0	14.3	13.7	11.4
DPS (Rs)	2.0	2.0	2.8	2.8


Source: *Consensus broker estimates, Company, Axis Capital

EM: Emerging market ^NCE: New chemical entity

Key drivers

Growth (%)	FY17E	FY18E	FY19E
core US (USD)	430	492	592
India	9	12	13
Core EBITDA margin (%)	18.4	20.6	22.6
core EPS (Rs/ sh)	26	40	53
core-EPS (%)	(23)	52	32

Price performance



(...continued from page 1)

- ♦ **FY18 guidance remains upbeat:** Guidance of 12-15% YoY revenue growth on reported basis in FY18. Management expects US business to grow in FY18 on the high gZetia base in FY17 aided by limited competition niche dermatology products awaiting approval. GNP expects 10 to 15 new launches in the US in FY18. It expects to deliver ~23% EBITDA margin in FY18 (vs. ~22% in FY17) as it expects improvement in business across segments
- ♦ **Net debt stagnant due to Venezuela related write-off:** Net debt marginally declined QoQ to Rs 36.67 bn. We note GNP has written off receivables/ cash from its Venezuela subsidiary of Rs 2.36 bn in its standalone P&L and ~Rs 3.25bn in consolidated balance sheet – netted vs. equity. Ex-Venezuela write-off (Rs 3.25bn), net debt would have reduced to Rs 33.5bn. GNP expects debt reduction below FY17 levels by end FY18
- ♦ **Other key highlights:** (1) **USFDA inspections** – Baddi facility did not receive any observation, but Goa facility received Form 483 with 4 observations; has responded to USFDA and awaiting approvals, (2) **R&D:** Guidance for 11-12% of sales for FY18 (vs. 11.8% in FY17); it has 65 pending ANDAs (of which 25 are Para IVs) with USFDA. Filed 9 in Q4, (3) **Tax:** Guided for ~25% tax rate in FY18 (vs. 23% tax in FY17), (4) **FY17 operating cash flow** at ~Rs. 12 bn and **cash tax** was high at Rs 7bn (vs. effective tax of Rs 3.4bn), (5) **Net working capital** days stand at 107 days vs. 114 days in H1 FY17. Receivable days at 98 days vs. 115 days in H1 FY17, inventory days at 87 days vs. 80 days in H1 FY17. Payable days at 107 days vs. 114 days in H1 FY17, (6) **FY17 capex** of Rs 7bn, (7) **Negative free cash flow** of Rs 2-2.25bn in FY17, (8) **Foreign Currency Translation Reserve (FCTR):** Venezuela related write-off of Rs 3.25bn. Other EM's subsidiaries had net positive impact of Rs 1.46bn. Net FCTR loss in FY17 was Rs 1.79bn and (9) **Net worth:** Net addition of Rs 6.7bn

Exhibit 1: US revenue declined sequentially due to slower ramp-up in gZetia

(Rs mn)	% of Q4 Sales	Q4'16	Q3'17	Q4'17	YoY (%)	QoQ (%)
US (USD mn)		97	183	150	54	(18)
US	41%	6,520	12,308	10,004	53	(19)
India	23%	5,398	5,169	5,769	7	12
Rest of the World (ROW)	12%	2,980	2,511	2,889	(3)	15
Europe	9%	2,705	1,957	2,298	(15)	17
Latin America	5%	2,416	947	1,340	(45)	41
API	8%	2,229	1,921	1,997	(10)	4
Consolidated Revenue		23,067	25,350	24,572	7	(3)

Source: Company

Exhibit 2: EBITDA margin declined sequentially on lower gZetia sales, higher R&D expense

(Rs mn)	Q4'16	Q3'17	Q4'17	YoY (%)	QoQ (%)
Net sales	23,067	25,350	24,572	7	(3)
Net sales	23,067	21,321	21,192	(8)	(1)
Gross margin	67.7	76.4	68.4	63 bps	-799 bps
Staff	3,482	4,017	3,847	11	(4)
% to sales	15.1	18.8	18.2	306 bps	-68 bps
Other expenses	6,661	4,933	4,880	(27)	(1)
% to sales	28.9	19.5	19.9	-902 bps	40 bps
R&D expense**	2,450	2,760	3,637	48	32
% to sales	10.6	10.9	14.8	418 bps	391 bps
EBITDA	3,035	7,650	4,438	46	(42)
EBITDA margin	13.2	30.2	18.1	491 bps	-1212 bps
Depreciation/Amortisation	584	625	689	18	10
Interest charge	475	617	697	47	13
Other income	117	146	(513)	(539)	(452)
PBT	2,092	6,553	2,540	21	(61)
Tax	604	1,794	(107)	(118)	(106)
Tax rate (%)	28.9	27.4	(4.2)	-3311 bps	-3160 bps
Reported PAT	1,488	4,759	1,838	23	(61)
Adjusted PAT*	1,488	4,759	3,997	169	(16)

Source: Company, As per IND-AS** Adjusted for Impairment loss (Rs 809mn), forex loss (Rs 1.35bn)

Exhibit 3: Guided for gross debt decline in FY18 below Mar'17 levels

(Rs mn)	Mar'16	Jun'16	Sept'16	Dec'16	Mar'17
Gross Debt	39,880	42,680	57,070	54,950	47,235
Cash	8,620	8,950	20,290	17,450	10,564
Net Debt	31,260	33,730	36,780	37,500	36,672

Source: Company

Conference call highlights
FY18 guidance

- ◆ **Revenue:** Expects 12-15% YoY growth on reported basis (despite high base of gZetia in FY17). Expects growth in US business on the high gZetia base in FY17
- ◆ **Margin:** Expects FY18 EBITDA margin of ~23% (22% in FY17), as it expects improvement in business across segments
- ◆ **R&D spends:** ~11-12% of sales for FY18 (vs. 11.8% in FY17)
- ◆ **Debt:** Expects net debt to decline in FY18 below FY17 levels
- ◆ **Tax rate:** ~25% tax rate in FY18

US business (USD 150 mn +54% YoY/-18% QoQ)

- ◆ ~15% price erosion within the base business in Q4. Additionally, the company received only 1 approval in H2FY17 vs. 10 approvals in H1FY17
- ◆ **gZetia** – Current run-rate marginally below lower end of initial guidance of USD 200-250mn within the 6 month exclusivity period
- ◆ Expects US business to grow YoY in FY18, on the high gZetia base in FY17, aided by limited competition niche dermatology products awaiting approval
- ◆ Expects 10 to 15 launches in US in FY18
- ◆ Goa Form 483 – GNP has received indication from USFDA; currently, awaiting approvals from the Goa facility

India formulations (Rs 5,769 mn, +7% YoY/ +12% QoQ)

- ♦ India growth was muted at 7% YoY owing to demonetization and destocking at the distributor end
- ♦ Management expects growth to rebound in FY18

RoW (Rs 2,889 mn, -3% YoY/15% QoQ)

- ♦ Russia: Recorded growth of 33% YoY YTD March 2017. Launched a nasal spray in Russia in Q4
- ♦ Asia and Africa business recorded below average performance. Launched 3 new products in Q4 in the region. The subsidiaries of South Africa and Kenya recorded good secondary sales growth in Q4

EU (Rs 2,289 mn, -15% YoY)

- ♦ Growth hit by depreciation of the GBP
- ♦ Mixed performance – Western European region recorded good growth in constant currency in Q4, while the Eastern European region recorded a decline in sales
- ♦ Growth in Western Europe was aided by the good performance of the UK and the German subsidiaries. In the fourth quarter, there were few product launches in the UK, Germany, Spain, and Poland
- ♦ Glenmark launched nearly 25 products across markets and in-licensed over 35 products in FY17
- ♦ Management expects good growth in FY18

LatAm (Rs. 1,340 mn, -45% YoY/41% QoQ)

- ♦ Sales affected by high base of Venezuela in Q4'16
- ♦ Mexico subsidiary recorded good sales growth; Brazil subsidiary's performance was average

R&D (Rs 3,080 mn, 14.8% of Q4'17 sales; 11.8% in FY17)

- ♦ Filed 9 ANDAs in Q4FY17 (vs. 11 in 9M'17) and got 1 approval (17 approvals in FY17: 11 FA + 6 TA); GNP plans to file 3 ANDA's in Q1'18.
- ♦ Filed 20 ANDA in FY17. Out of these, 9 were dermatological products, 3 were hormonal products, 1 was Oncology injectable and 7 applications were oral solids out of which majority were complex or niche products
- ♦ GNP has 65 pending ANDA (of which 25 are Para IVs)
- ♦ GSP 301: Plans to meet with the FDA to discuss the 505(b)(2) New Drug Application (NDA) filing strategy in the second half of CY 2017.

B/S and C/F highlights


- ♦ Gross debt at Rs 47.23 bn while net debt marginally declined QoQ at Rs 36.67 bn. Expects net debt to decline in FY18 vs. FY17 levels
- ♦ Net working capital days stand at 107 days vs. 114 days in H1FY17. Receivable days stood at 98 days vs. 115 days in H1FY17, inventory days at 87 days vs. 80 days in H1FY17. Payable days at 107 days vs. 114 days in H1FY17
- ♦ Operating cash flow for FY17 was ~Rs 12 bn. Cash tax of Rs 7bn in FY17 (vs. effective tax of Rs 3.4bn). Negative FCF for FY17 of Rs 2-2.5bn
- ♦ Venezuela related write-off at Rs 3.25 bn. Ex Venezuela write-off, net debt would have stood at Rs 33.42bn vs. reported net debt of Rs 36.67bn

- ◆ Forex loss of Rs 1.39bn in Q4; Rs 650 mn was reversed in other income, as there was a forex gain in 9MFY17 and the remaining in other expenses
- ◆ Foreign Currency Translation Reserve (FCTR): Venezuela related write-off at Rs 3.25bn. Other EM's resulted in gains of Rs 1.46bn. Net FCTR loss in FY17 was Rs 1.79bn
- ◆ Net worth: FY17 net addition of Rs 6.7bn
- ◆ Interest cost of Rs. 697 mn has a cash component of Rs. 460 mn vs. cash component of Rs 490mn in Dec'16
- ◆ Other expenses increased due to R&D and higher selling and distribution costs


Exhibit 4: Market share in key products improving

Generic name	Brand name	Brand sales / mkt size (USD mn)	#No. of players	Market share (%)						
				Mar'16	Jun'16	Sep'16	Dec'16	Jan'17	Feb'17	Mar'17
Ezetimibe*	Zetia	2,300	2	-	-	-	20%	46%	48%	48%
Rosuvastatin Calcium	Crestor	6,780	>10	-	-	10%	11%	10%	7%	7%
Calcipotriene cream	Dovonex	93	3	15%	19%	24%	26%	27%	31%	36%
Nystatin-Triam cream	Mycalog - II	145	3	-	-	-	3%	5%	5%	8%
Nystatin-Triam Ointment	Kenalog	38	4	-	-	-	2%	4%	6%	7%
Diclofenac Sodium Gel	Solaraze	297	4	-	-	-	10%	10%	9%	9%
Trandolapril + Verampil Hcl	Tarka	24	2	46%	45%	41%	44%	44%	49%	47%
Raloxifene Hcl	Evista	337	7	-	2%	6%	10%	10%	10%	10%
Mupirocin ointment	Bactroban	55	6	21%	27%	27%	27%	28%	27%	28%
Mupirocin cream	Bactroban	55	2	87%	98%	99%	99%	99%	99%	99%

Source: Bloomberg

Exhibit 5: R&D expense significantly higher in Q4


Source: Company

Exhibit 6: To file 3 ANDAs in Q1'18


Source: Company

Exhibit 7: Increasing focus on niche segments

Pending ANDA	Jun-13	Apr-14	Dec-14	Mar-15	Dec-15	Jun-16	Sep-16
Immediate Release	12	29	31	31	28	31	31
Hormones	5	13	14	11	8	5	6
Dermatology	5	8	10	15	12	15	11
Others*	5	7	6	6	6	5	5
Injectables	3	7	13	13	8	7	8
Total	53	64	74	76	62	63	61
Para IVs	23	29	39	33	26	22	23

Source: Company *Note: Others include Modified release, Controlled substance, immunosuppressants

Exhibit 8: Key complex generic products in pipeline


Product	Market Size (USD bn)	Source	Filing Status			
			Filed	CY17	CY18	CY19
gWelchol	0.6	In-House	✓			
gRenagel	2.1	In-House	✓			
gVagifem	0.4	In-House		✓		
gConcerta	1.8	In-License			✓	
gAbraxane	0.7	In-License				✓
gSuboxone	1.6	In-License				✓
gNuvaring	0.8	In-License				✓
GSP 101 (Gx Inhaler)	~4.5	In-House			✓	
GSP 103 (Gx Inhaler)	~1.0	In-House			✓	
GSP 104 (Gx Inhaler)	~0.8	In-House				✓

Source: Company

Exhibit 9: Expects to file 9 NDA/BLA in next decade across NME and specialty portfolio


Therapy Area	Molecule	Status	Filing Timelines (NDA/BLA)				
			2019	2020	2021	2022	2023+
Respiratory	GSP 301	Phase 3	✓				
	GSP 304	Phase 2	✓				
	GBR 310	Pre Clinical		✓			
	GRC 388XX	Pre Clinical					✓
Dermatology	GBR 830	Phase 2				✓	
Oncology	GBR 1302	Phase 1				✓	
	GBR 1342	Pre Clinical					✓
	GBR 1372	Pre Clinical					✓
	GBR 8383	Pre Clinical					✓

Source: Company

Exhibit 10: IPM posted lower volume growth in Q4


Source: AIOCD

IPM = India Pharma market

Exhibit 11: GNP growth led by new launches/ volume pickup in Q4


Source: AIOCD

Exhibit 12: Strong growth seen in Respiratory and Anti-Infective segments in Q4

YoY growth	% of sales	FY16	FY17	Q1'17	Q2'17	Q3'17	Q4'17
Derma	28%	25%	13%	17%	9%	11%	12%
Cardiac	22%	23%	8%	8%	3%	13%	9%
Respiratory	16%	23%	19%	4%	40%	7%	19%
Anti-Infectives	14%	15%	13%	-3%	23%	9%	24%
Anti-Diabetic	7%	26%	-16%	-7%	-26%	-23%	-6%
Gastro Intestinal	3%	24%	56%	8%	59%	85%	68%
Vitamin/ Min / Nut	2%	16%	2%	36%	-10%	-2%	-9%
Pain / Analgesics	2%	7%	-2%	7%	-6%	-3%	-10%
Gynaecological	3%	13%	30%	15%	31%	49%	30%
Ophthal/Otologicals	1%	23%	2%	-8%	15%	-6%	6%
Total (Rs bn)	27	23%	12%	8%	14%	11%	15%

Source: AIOCD

Financial summary (Consolidated)

Profit & loss (Rsmn)

Y/E March	FY16	FY17	FY18E	FY19E
Net sales	76,496	91,857	96,485	1,09,809
Other operating income	-	-	-	-
Total operating income	76,496	91,857	96,485	1,09,809
Cost of goods sold	(23,026)	(26,143)	(27,498)	(31,032)
Gross profit	53,470	65,714	68,987	78,777
<i>Gross margin (%)</i>	<i>69.9</i>	<i>71.5</i>	<i>71.5</i>	<i>71.7</i>
Total operating expenses	(39,142)	(45,347)	(47,929)	(53,954)
EBITDA	14,328	20,367	21,058	24,823
<i>EBITDA margin (%)</i>	<i>18.7</i>	<i>22.2</i>	<i>21.8</i>	<i>22.6</i>
Depreciation	(2,691)	(3,168)	(3,192)	(3,625)
EBIT	11,636	17,199	17,866	21,198
Net interest	(1,789)	(2,373)	(1,809)	(1,624)
Other income	200	373	383	392
Profit before tax	10,047	15,199	16,440	19,966
Total taxation	(3,026)	(3,442)	(4,110)	(4,991)
<i>Tax rate (%)</i>	<i>30.1</i>	<i>22.6</i>	<i>25.0</i>	<i>25.0</i>
Profit after tax	7,021	11,757	12,330	14,974
Minorities	-	-	-	-
Profit/ Loss associate co(s)	-	-	-	-
Adjusted net profit	7,021	11,757	12,330	14,974
<i>Adj. PAT margin (%)</i>	<i>9.2</i>	<i>12.8</i>	<i>12.8</i>	<i>13.6</i>
Net non-recurring items	-	-	-	-
Reported net profit	7,021	11,757	12,330	14,974

Balance sheet (Rsmn)

Y/E March	FY16	FY17	FY18E	FY19E
Paid-up capital	282	282	282	282
Reserves & surplus	42,420	49,112	60,489	74,511
Net worth	42,702	49,394	60,771	74,793
Borrowing	40,244	47,662	42,781	38,405
Other non-current liabilities	1,356	572	572	572
Total liabilities	84,299	97,624	1,04,120	1,13,766
Gross fixed assets	51,460	55,764	62,764	69,764
Less: Depreciation	(11,810)	(14,978)	(18,170)	(21,795)
Net fixed assets	39,650	40,787	44,595	47,969
Add: Capital WIP	-	-	-	-
Total fixed assets	39,650	40,787	44,595	47,969
Total Investment	172	157	157	157
Inventory	15,678	21,390	22,469	24,068
Debtors	24,926	24,043	25,113	27,076
Cash & bank	8,571	10,564	9,028	10,665
Loans & advances	10,289	13,265	14,539	16,547
Current liabilities	24,061	24,496	25,668	28,599
Net current assets	35,404	44,766	45,481	49,756
Other non-current assets	9,073	11,914	13,887	15,884
Total assets	84,299	97,624	1,04,120	1,13,766

Source: Company, Axis Capital

Cash flow (Rsmn)

Y/E March	FY16	FY17	FY18E	FY19E
Profit before tax	10,047	15,199	16,440	19,966
Depreciation & Amortisation	2,691	3,168	3,192	3,625
<i>Chg in working capital</i>	<i>(6,077)</i>	<i>(6,174)</i>	<i>(3,146)</i>	<i>(2,116)</i>
Cash flow from operations	3,448	8,113	11,829	15,719
<i>Capital expenditure</i>	<i>(8,903)</i>	<i>(7,000)</i>	<i>(7,000)</i>	<i>(7,000)</i>
Cash flow from investing	(8,802)	(7,000)	(7,000)	(7,000)
<i>Equity raised/ (repaid)</i>	<i>18,944</i>	<i>-</i>	<i>-</i>	<i>-</i>
<i>Debt raised/ (repaid)</i>	<i>110</i>	<i>7,418</i>	<i>(4,881)</i>	<i>(4,376)</i>
<i>Dividend paid</i>	<i>(679)</i>	<i>(681)</i>	<i>(953)</i>	<i>(953)</i>
Cash flow from financing	16,575	4,364	(7,643)	(6,952)
Net chg in cash	11,222	5,478	(2,814)	1,767

Key ratios

Y/E March	FY16	FY17	FY18E	FY19E
OPERATIONAL				
FDEPS (Rs)	24.8	41.6	43.6	53.0
CEPS (Rs)	34.4	52.8	54.9	65.8
DPS (Rs)	2.0	2.0	2.8	2.8
Dividend payout ratio (%)	8.0	4.8	6.4	5.3
GROWTH				
Net sales (%)	15.1	20.1	5.0	13.8
EBITDA (%)	16.9	42.2	3.4	17.9
Adj net profit (%)	(12.6)	67.4	4.9	21.4
FDEPS (%)	(16.2)	67.4	4.9	21.4
PERFORMANCE				
RoE (%)	19.3	25.5	22.4	22.1
RoCE (%)	15.2	19.3	18.1	19.8
EFFICIENCY				
Asset turnover (x)	1.1	1.1	1.1	1.1
Sales/ total assets (x)	0.7	0.8	0.8	0.8
Working capital/ sales (x)	0.3	0.3	0.4	0.3
Receivable days	118.9	95.5	95.0	90.0
Inventory days	92.0	109.2	108.7	103.4
Payable days	113.9	97.2	94.8	93.1
FINANCIAL STABILITY				
Total debt/ equity (x)	1.1	1.0	0.8	0.6
Net debt/ equity (x)	0.9	0.8	0.6	0.4
Current ratio (x)	2.5	2.8	2.8	2.7
Interest cover (x)	6.5	7.2	9.9	13.1
VALUATION				
PE (x)	36.4	21.7	20.7	17.1
EV/ EBITDA (x)	20.0	14.3	13.7	11.4
EV/ Net sales (x)	3.7	3.2	3.0	2.6
PB (x)	6.0	5.2	4.2	3.4
Dividend yield (%)	0.2	0.2	0.3	0.3
Free cash flow yield (%)	-	-	-	-

Source: Company, Axis Capital

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
3. ASL has no material adverse disciplinary history as on the date of publication of this report.
4. I/We, authors (Research team) and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associates do not have any material conflict of interest. I/we have not served as director, officer or employee in the subject company.

Research Team

Sr. No	Name	Designation	E-mail
1	Akhand Singh	Research Analyst	akhand.singh@axissecurities.in
2	Poonam Darade	Research Associate	poonam.darade@axissecurities.in

5. ASL or its associates has not received any compensation from the subject company in the past twelve months. ASL or its Research Analysts has not been engaged in market making activity for the subject company.

6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

- i. Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;
- ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or;
- iii. Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.

DEFINITION OF RATINGS	
Ratings	Expected absolute returns over 12-18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, Corporate office: Unit No. 2, Phoenix Market City, 15, LBS Road, Near Kamani Junction, Kurla (west), Mumbai-400070, Tel No. – 18002100808/022-61480808, Regd. off.- Axis House, 8th Floor, Wadia International Centre, PandurangBudhkarMarg, Worli, Mumbai – 400 025. Compliance Officer: AnandShaha, Email: compliance.officer@axisdirect.in, Tel No: 022-42671582.